Get started
Author

Fanny Bouquet

Observed names: Bouquet, F, Bouquet, Fanny, F Bouquet, F. Bouquet
Observed institutions: Roche (Switzerland), Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier, Université de Bourgogne, University of California, San Francisco, University of Michigan, Institut Gustave Roussy, NYU Langone Health, Centre Georges François Leclerc, Institut de Pharmacologie et de Biologie Structurale, NVH Medicinal (France), Roche (France), Laboratoire d’Électronique, Informatique et Image, UCSF Helen Diller Family Comprehensive Cancer Center, Institut de Chimie Moléculaire de l'Université de Bourgogne, Université de Toulouse, New York University
ORCID: 0000-0002-3209-1344
Observed ORCID: 0000-0002-3209-1344
OpenAlex ID: A5035214848
TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo
2011 · Fanny Bouquet, Anupama Pal, et al. · Clinical Cancer Research · 240
PDF
The Loss of γH2AX Signal is a Marker of DNA Double Strand Breaks Repair Only at Low Levels of DNA Damage
2006 · Fanny Bouquet, Catherine Muller, et al. · Cell Cycle · 125
PDF
A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia
2011 · Fanny Bouquet, Marielle Ousset, et al. · Journal of Cell Science · 91
PDF
Loss of ATM positively regulates the expression of hypoxia inducible factor 1 (HIF-1) through oxidative stress: Role in the physiopathology of the disease
2010 · Marielle Ousset, Fanny Bouquet, et al. · Cell Cycle · 51
PDF
Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer
2018 · Anne Rodallec, Jean-Michel Brunel, et al. · International Journal of Nanomedicine · 48
PDF
From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer
2018 · Anne Rodallec, Guillaume Sicard, et al. · International Journal of Nanomedicine · 36
PDF
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer
2024 · Antonin Levy, Daphné Morel, et al. · Molecular Cancer · 35
PDF
Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer
2022 · Sandra Ortiz-Cuaran, Aurélie Swalduz, et al. · European Journal of Cancer · 35
Multimodal imaging based on MRI and PET reveals [18F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma
2015 · Aurélien Corroyer-Dulmont, Elodie A. Pérès, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 29
Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles
2020 · A. Rodallec, C. Franco, et al. · Scientific Reports · 25
PDF
Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
2017 · Judith Raimbourg, Marie-Pierre Joalland, et al. · Molecular Cancer Therapeutics · 24
Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3)
2019 · Anne Rodallec, Guillaume Sicard, et al. · Anti-Cancer Drugs · 21
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAF V600E Melanoma Lines with Vemurafenib
2017 · Alexandra Frazao, Marina Colombo, et al. · Cancer Immunology Research · 20
Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways
2020 · J. Vial, P. Huchedé, et al. · Cell Death Discovery · 18
PDF
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results
2025 · Antonin Levy, Daphné Morel, et al. · Signal Transduction and Targeted Therapy · 16
Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
2019 · Coralie Reger de Moura, Laetitia Vercellino, et al. · Translational Oncology · 16
Tetraspanin8 expression predicts an increased metastatic risk and is associated with cancer-related death in human cutaneous melanoma
2021 · Odile Berthier-Vergnes, Laetitia Barbollat-Boutrand, et al. · Molecular Cancer · 8
PDF
Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.
2022 · Chris Labaki, Ziad Bakouny, et al. · Journal of Clinical Oncology · 7
Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
2022 · Bernadett Szabados, Mariano Ponz-Sarvisé, et al. · Clinical Cancer Research · 5
Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL
2026 · Paul Marcoux, Fabien Gava, et al. · Blood · 4
Abstract 3709: Characterization, in vitro and in vivo efficacy studies of docetaxel trastuzumab stealth immunoliposome in human breast cancer models
2018 · Anne Rodallec, Jean Michel Brunel, et al. · Cancer Research · 4
252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience
2022 · C. Labaki, Z. Bakouny, et al. · Annals of Oncology · 3
PDF
DNA repair-based classification of melanoma cell lines reveals an effect of mutations in BRAF and NRAS driver genes on DNA repair capacity
2020 · Sylvie Sauvaigo, Manel Benkhiat, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Abstract CT089: Clinical and translational results of the academic ARIANES Phase 2 basket study: Longitudinal bulk and single-cell RNAseq analyses of patient tumors identify biological correlates of response to PARP inhibitors and anti-PD-L1 therapy
2025 · Thibault Thomas-Bonafos, Julien Vibert, et al. · Cancer Research · 1
Monocyte/lymphocyte ratio to predict immunoradiotherapy response in patients with advanced pretreated sarcoma.
2024 · Antonin Levy, Daphné Morel, et al. · Journal of Clinical Oncology · 1
PDF
Works count: 118
Citation count: 869
H-index: 16
I10-index: 16
Year
Topic
Type